SciClone Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Transcription

1 Brochure More information from SciClone Pharmaceuticals, Inc. - Product Pipeline Review - Q Description: SciClone Pharmaceuticals, Inc. Product Pipeline Review Q Summary Global Market Direct s pharmaceuticals report, SciClone Pharmaceuticals, Inc. - Product Pipeline Review - Q provides data on the company s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct s proprietary databases, Company s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct s team. Scope - SciClone Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of SciClone Pharmaceuticals, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of SciClone Pharmaceuticals, Inc. with complete description of the product s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the SciClone Pharmaceuticals, Inc. s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate SciClone Pharmaceuticals, Inc. s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of SciClone Pharmaceuticals, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the SciClone Pharmaceuticals, Inc. s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with SciClone Pharmaceuticals, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of SciClone Pharmaceuticals, Inc. and identify potential opportunities in those areas. Contents: List of Tables List of Figures SciClone Pharmaceuticals, Inc. Snapshot SciClone Pharmaceuticals, Inc. Overview Key Information Key Facts SciClone Pharmaceuticals, Inc. Research and Development Overview Key Therapeutic Areas SciClone Pharmaceuticals, Inc. Pipeline Review Pipeline Products by Stage of Development Pipeline Products Monotherapy Pipeline Products Combination Treatment Modalities

2 SciClone Pharmaceuticals, Inc. Pipeline Products Glance SciClone Pharmaceuticals, Inc. Clinical Stage Pipeline Products Phase II Products/Combination Treatment Modalities SciClone Pharmaceuticals, Inc. Drug Profiles RP101 + Gemcitabine SCV-07 SCV-07 + Ribavirin SciClone Pharmaceuticals, Inc. Pipeline Analysis SciClone Pharmaceuticals, Inc. Pipeline Products by Therapeutic Class SciClone Pharmaceuticals, Inc. Pipeline Products By Target SciClone Pharmaceuticals, Inc. Recent Pipeline Updates SciClone Pharmaceuticals, Inc. - Dormant Projects SciClone Pharmaceuticals, Inc. Company Statement SciClone Pharmaceuticals, Inc. Locations And Subsidiaries Head Office Other Locations & Subsidiaries Recent Developments Sep 29, 2010: SciClone Identifies Unique Genetic Markers Associated With Patient Response To SCV-07 Treatment In Jun 30, 2010: SciClone And Sigma-Tau Report Final Data From Clinical Trial Of ZADAXIN As H1N1 Vaccine Enhancer May 17, 2010: SciClone Provides Further Topline Results From Phase II Study Of SCV-07 For Prevention Of May 17, 2010: SciClone Provides Further Topline Results From Phase II Study Of SCV-07 For Prevention Of Mar 30, 2010: SciClone Announces Topline Results From Phase II Clinical Trial Of SCV-07 For Prevention Of Mar 24, 2010: SciClone Receives European Approval For Ondansetron RapidFilm To Treat Nausea And Vomiting Feb 08, 2010: SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN's Ability To Enhance Response To H1N1 Vaccine Feb 08, 2010: SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN's Ability To Enhance Response To H1N1 Vaccine Jan 12, 2010: Sciclone Pharmaceuticals And Sigma-Tau Announce Positive Results In Clinical Study Examining Of ZADAXIN Nov 30, 2009: SciClone Announces Commencement And Complete Enrollment Of Clinical Study Examining Zadaxin s Ability To Enhance The H1N1 Vaccine Financial Deals Landscape SciClone Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010 SciClone Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010 SciClone Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010 SciClone Pharmaceuticals, Inc. Detailed Deal Summary SciClone Pharmaceuticals Enters Into Co-Development Agreement With Nektar Therapeutics Licensing Agreements SciClone Pharmaceuticals Enters Into Licensing Agreement With APR Applied Pharma SciClone Enteres Into Licensing Agreement With Resistys SciClone Enteres Into Agreement With Biocomaptibles Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us

3 Disclaimer Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,

4 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: SciClone Pharmaceuticals, Inc. - Product Pipeline Review - Q Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Single User: Site License: Enterprisewide: Quantity USD 500 USD 1000 USD 1500 * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

5 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World